Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Marla L. Watt"'
1
Akademický článek
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy
Autor: Mali Cosden, Sarah Jinn, Lihang Yao, Cheryl A. Gretzula, Monika Kandebo, Dawn Toolan, Nathan G. Hatcher, Lei Ma, Wei Lemaire, Gregory C. Adam, Christine Burlein, Christina Minnick, Rose Flick, Marla L. Watt, James Mulhearn, Mark Fraley, Robert E. Drolet, Jacob N. Marcus, Sean M. Smith
Publikováno v: Neurobiology of Disease, Vol 159, Iss , Pp 105507- (2021)
Mutations in the lysosomal enzyme glucocerebrosidase (GCase, GBA1 gene) are the most common genetic risk factor for developing Parkinson's disease (PD). GCase metabolizes the glycosphingolipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSp
Externí odkaz: https://doaj.org/article/5bb119e476704557a1fe920f9ef43979
Zobrazit plný text záznamu
3
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy
Autor: Marla L. Watt, Sarah Jinn, Nathan G. Hatcher, Lei Ma, Mali Cosden, Monika Kandebo, Christine Burlein, Christina Minnick, Mark E. Fraley, Cheryl A. Gretzula, Wei Lemaire, Rose B. Flick, Sean M. Smith, James Mulhearn, Gregory C. Adam, Jacob Marcus, Robert E. Drolet, Dawn Toolan, Lihang Yao
Publikováno v: Neurobiology of Disease, Vol 159, Iss, Pp 105507-(2021)
Mutations in the lysosomal enzyme glucocerebrosidase (GCase, GBA1 gene) are the most common genetic risk factor for developing Parkinson's disease (PD). GCase metabolizes the glycosphingolipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38cd5da06600d31f6c7bb67bb7f45f07
https://doi.org/10.1016/j.nbd.2021.105507
Zobrazit plný text záznamu
4
Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain
Autor: Christian C. Felder, Ed Siuda, Chuanxi Xiang, Hongling Xiao, James A. Monn, Lourdes Prieto, Anne T. Quets, David L. McKinzie, Beverly A. Heinz, Marla L. Watt, Douglas A. Schober, Yuan Tu, Eric S. Nisenbaum
Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 361:190-197
LY2812223 [(1R,2S,4R,5R,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid] was identified via structure-activity studies arising from the potent metabotropic glutamate mGlu2/3 receptor agonist LY354740 [(+)-2-ami
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbf1c55697faf52f729e7376c25a77a1
https://doi.org/10.1124/jpet.116.237859
Zobrazit plný text záznamu
5
Characterization of PCS1055, a novel muscarinic M4 receptor antagonist
Autor: Wai Y. Chan, Christian C. Felder, Andrea M. Castetter, Marla L. Watt, Anne T. Quets, Carrie H. Croy
Publikováno v: European Journal of Pharmacology. 782:70-76
Identification of synthetic ligands selective for muscarinic receptor subtypes has been challenging due to the high sequence identity and structural homology among the five muscarinic acetylcholine receptors. Here, we report the pharmacological chara
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d9c1e9baedc31c537c519a58c6fc99a
https://doi.org/10.1016/j.ejphar.2016.04.022
Zobrazit plný text záznamu
6
Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists
Autor: David L. McKinzie, Bin Liu, Christian C. Felder, G. Stuart Gregory, Marla L. Watt, Robert E. Stratford, Carrie H. Croy, Hoogestraat Paul J, Jennifer R. Allen, James Andrew Jamison, Zhigang Rao, David A. Evans, William W. Turner, Frank P. Bymaster, Stephen Hitchcock, Mark G. Bures, Marvin M. Hansen, Fese M. Okha-Mokube
Publikováno v: Bioorganic & Medicinal Chemistry Letters. 25:4158-4163
The observation that cholinergic deafferentation of circuits projecting from forebrain basal nuclei to frontal and hippocampal circuits occurs in Alzheimer's disease has led to drug-targeting of muscarinic M1 receptors to alleviate cognitive symptoms
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::460bbb7f85712e78446c74ee34c30d7f
https://doi.org/10.1016/j.bmcl.2015.08.011
Zobrazit plný text záznamu
7
Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist
Autor: Marla L. Watt, Bin Liu, David L. McKinzie, Douglas A. Schober, Stephen H Hitchcock, Christian C. Felder, Amy K. Chesterfield
Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 338:622-632
Alzheimer's disease and schizophrenia are characterized by expression of psychotic, affective, and cognitive symptoms. Currently, there is a lack of adequate treatment for the cognitive symptoms associated with these diseases. Cholinergic signaling a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9d2ecaacd180f747c396d3a60dc723d
https://doi.org/10.1124/jpet.111.182063
Zobrazit plný text záznamu
8
The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype
Autor: Marla L. Watt, David B. Shaw, Linda M. Rorick-Kehn, Christian C. Felder, Anne T. Quets, Amy K. Chesterfield, Karen M. Knitowski, David L. McKinzie
Publikováno v: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 38(13)
The generation of muscarinic acetylcholine receptor (mAChR) subtype-selective compounds has been challenging, requiring use of nonpharmacological approaches, such as genetically engineered animals, to deepen our understanding of the potential that me
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::513036dfca18d31e718f3314854f2429
https://pubmed.ncbi.nlm.nih.gov/23907402
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje